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A key characteristic of hematopoietic stem cells
(HSCs) is the ability to self-renew. Genetic deletion
of b-catenin during fetal HSC development leads
to impairment of self-renewal while b-catenin is
dispensable in fully developed adult HSCs. Whether
b-catenin is required for maintenance of fully devel-
oped CML leukemia stem cells (LSCs) is unknown.
Here, we use a conditional mouse model to show
that deletion of b-catenin after CML initiation does
not lead to a significant increase in survival.
However, deletion of b-catenin synergizes with ima-
tinib (IM) to delay disease recurrence after imatinib
discontinuation and to abrogate CML stem cells.
These effects can be mimicked by pharmacologic
inhibition of b-catenin via modulation of prosta-
glandin signaling. Treatment with the cyclooxyge-
nase inhibitor indomethacin reduces b-catenin levels
and leads to a reduction in LSCs. In conclusion,
inhibiting b-catenin by genetic inactivation or phar-
macologic modulation is an effective combination
therapy with imatinib and targets CML stem cells.
INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative
neoplasia (MPN) characterized by massive proliferation of
phenotypically normal mature myeloid cells. This disease is initi-
ated by a reciprocal translocation of chromosomes 9 and 22
resulting in the generation of a constitutively active fusion kinase,
BCR-ABL (Ben-Neriah et al., 1986; Druker, 2008). This onco-
genic fusion is capable of transforming hematopoietic stem cells
(HSCs) and is sufficient to initiate MPN in murine bone marrow
(BM) transplantation models (Daley et al., 1990). Targeted
therapy using small molecule inhibitors of BCR-ABL such as
imatinib (IM) (Druker et al., 1996, 2001) or second generation
kinase inhibitors such as dasatinib or nilotinib (Kantarjian et al.,412 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.2010; Saglio et al., 2010) has revolutionized therapy for CML,
but in the overwhelming majority of patients, the disease clone
is not eliminated, an effect that has been attributed to a persistent
leukemia stem cell (LSC) pool that is inherently resistant to these
targeted therapies. LSCs in CML share immunophenotypic
features with normal HSCs, reside in the BM, and are resistant
to IM treatment, despite inhibition of BCR-ABL (Corbin et al.,
2011; Hu et al., 2009). Upon discontinuation of IM therapy, these
LSCs are able to re-establish CML and to cause disease relapse
(Savona and Talpaz, 2008).
A key characteristic of stem cells is their ability to self-renew.
Several genes and signaling pathways control the fine balance
between self-renewal and differentiation in HSCs and potentially
also in LSCs. One such pathway is the canonical Wnt pathway
(Jamieson et al., 2004; Majeti et al., 2009; Malhotra and Kincade,
2009; Mu¨ller-Tidow et al., 2004; Reya et al., 2003; Zhao et al.,
2007). b-catenin, the pathway’s central effector molecule, is
negatively regulated via phosphorylation by a multiprotein
complex including APC, Axin, GSK-3b, and casein kinase (Beh-
rens et al., 1998; Rubinfeld et al., 1996). Several compounds
interacting with this pathway in a variety of cancers are currently
being investigated in preclinical studies (Chen et al., 2009;
Huang et al., 2009; Peterson et al., 2009). Prostaglandin E2 is
known to promote stabilization of b-catenin in colon cancer
(Castellone et al., 2005) and can be modified by inhibition of its
upstream regulator cyclooxygenase (COX). Recently, interfer-
ence of prostaglandin signaling has been shown to target the
Wnt/b-catenin axis in HSCs (Goessling et al., 2009) and acute
myeloid leukemia (AML) stem cells (Wang et al., 2010). Abroga-
tion of b-catenin by the cyclooxygenase inhibitor indomethacin
led to a 100-fold decrease in AML-initiating cells in secondary
recipients. Moreover, indomethacin treatment of fully devel-
oped, MLL-AF9-induced leukemia led to reduction of b-catenin
levels and caused reduction of LSC frequency. These data indi-
cate that certain subtypes of AML retain dependency on Wnt
signaling.
Recent studies have shed light on the impact of Wnt/b-catenin
activity on development of BCR-ABL-induced MPN in several
CML mouse models. Deletion of b-catenin in HSC development
(using vav-Cre) (Zhao et al., 2007) or concurrently with activation
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2009) inCtnnb1fl/fl knockoutmouse BM led to impaired leukemo-
genesis. These studies clearly indicate that b-catenin plays a role
in the development of normal HSCs and BCR-ABL-induced
CML. However, b-catenin is not required for maintenance of
normal self-renewal in fully developed HSCs, which prompts
the question whether b-catenin is required for maintenance of
BCR-ABL-induced CML LSCs. This question is critical for thera-
peutic targeting of LSCs in chronic-phaseCMLpatients. Further-
more, given that all patients with CML are treated with tyrosine
kinase inhibitors, it is important to determine the effects of
pathwaymodulation in this context.We therefore aimed to inves-
tigate the impact of b-catenin modulation in established and
IM-treated BCR-ABL-induced CML.
RESULTS
Genetic Deletion of b-Catenin Reduces Bone Marrow
and Peripheral Blood CML Cells
In order to address whether b-catenin is required for LSC main-
tenance, we aimed to delete b-catenin in BM cells after the
engraftment of BCR-ABL-transduced stem cells in primary
recipient mice. BM from mice with the genotypes Ctnnb1fl/fl
Esr1-Cre+, Ctnnb1+/fl Esr1-Cre+, and Ctnnb1+/+ Esr1-Cre+ were
transduced with a retrovirus encoding human p210-BCR-ABL
and GFP (MSCV-BCR-ABL-IRES-GFP) and injected into wild-
type syngeneic recipient mice. Recipient mice were then fol-
lowed for establishment of disease by assessment of GFP+ cells
in the peripheral blood after BM transplantation. Upon confirma-
tion of GFP+ cells (>3%) in peripheral blood, tamoxifen (TAM)
was introduced via intraperitoneal injection (generally starting
day +14). Mice were then followed for survival, and unexpect-
edly, recipient mice of Ctnnb1fl/fl Esr1-Cre+ (Ctnnb1/) BM
showed similar survival to treated wild-type or untreated
controls, with all mice succumbing to a CML-like disease
between 3 and 5 weeks after BM transplantation (Figure 1A).
There was no significant survival difference detectable between
the different treatment cohorts, although there was a trend for
the Ctnnb1/ group (p = .12). b-catenin excision was shown
by PCR in Ctnnb1/ recipients, demonstrating excision in the
majority of GFP-sorted cells (Figure S1 available online). Upon
analysis of moribund animals, we recognized that organ infiltra-
tion (especially hemorrhagic pulmonary infiltrates) was compa-
rable in all treatment groups (Figure 1C). In contrast, there was
a clear difference detectable with regard to BM and blood
involvement. White blood counts were significantly lower in the
Ctnnb1/ (p = .0149*) group compared to TAM-treated WT
controls (Figure 1B). BM samples of each mouse showed
decreased GFP+ cells in Ctnnb1/mice (Figure 1D). This differ-
ence was noted in both the total GFP+ fraction as well as the
GFP+/Sca1+ fraction of individually analyzed BM samples from
each group (Figure 1D). Significantly, it is this GFP+Sca1+ popu-
lation that is enriched for LSCs in that transplantation of these
cells is sufficient to reconstitute MPN in secondary recipients
(Hu et al., 2009). These data suggest that conditional b-catenin
deletion after onset of BCR-ABL-induced disease predominantly
reduces more immature hematopoietic cells, including pheno-
typic LSCs, as compared to more mature cells that have infil-
trated organs such as the lung.Combination of IM and b-Catenin Deletion Results
in Delayed CML Recurrence after IM Discontinuation
Tyrosine kinase inhibitors such as imatinib (IM) are established
as the first-line therapy for patients with CML, resulting in high
rates of hematologic, cytogenetic, and molecular remissions.
However, withdrawal of IM, even in patients that had achieved
a complete molecular remission, results in relapsed disease
in the majority of patients (Ross et al., 2010). This has been
hypothesized to reflect a resistant and quiescent LSC population
that can regenerate disease in the event of treatment interruption
(Mahon et al., 2010; Ross et al., 2010; Rousselot et al., 2007).
Based on this, we hypothesized that the combination of IM
therapy, which targets most cells other than the LSC population,
with Wnt/b-catenin pathway modulation, which should target
more immature LSC-like cells, might delay relapse after IM with-
drawal. Transplantation-related reconstitution/engraftment of
genetically modified cells is always an issue when investigating
leukemia development. Therefore, our experiment (Figure 2)
was specifically designed to take the transplantation-related
reconstitution/engraftment out of the equation. To address
this, we examined whether activation or inhibition of Wnt/b-cat-
enin signaling could have an effect on disease relapse after
discontinuation of IM treatment. Wnt/b-catenin signaling is
known to regulate the cell cycle in HSCs and constitutive activa-
tion is associated with loss of quiescence and stem cell exhaus-
tion (Gothot et al., 1998; Kirstetter et al., 2006; Passegue´
et al., 2005; Scheller et al., 2006). To model constitutive activa-
tion of b-catenin, we used a validated model of enhanced
Wnt signaling, Apcmin mice (Lane et al., 2010). We assessed
inactivation by using Ctnnb1fl/fl Esr1-Cre+ mice or the appro-
priate wild-type mice (Ctnnb1+/+ Esr1-Cre+, Ctnnb1+/+ Esr1-
Cre) as BM donors. 5-FU-treated BM cells of donor mice (as
indicated above) were infected with the p210-BCR-ABL retro-
viral construct and injected into syngeneic recipients. After
engraftment, IM treatment was initiated followed by TAM treat-
ment to induce b-catenin deletion (Figure 2A). After 3 weeks,
IM treatment was discontinued and mice were monitored for
disease progression. All mice were analyzed for disease burden
after the first animal had to be sacrificed according to the animal
facility guidelines. BM, spleen, and peripheral blood were
analyzed for signs of MPN. All wild-type animals investigated
at that early time point had a significant amount of disease
burden, so the first animal is not likely to be an outlier.
White blood counts were significantly lower in animals where
b-catenin was deleted as compared to wild-type-recipient
controls (p = .048*); however, recipients of Apcmin BM showed
similar levels compared to wild-type recipients (Figure 2B, left).
Given the short time after IM discontinuation, no significant
differences in spleen size were detected (Figure 2B, right).
Investigating the BM, however, revealed greater than 100-fold
reduction of GFP+ cells and GFP+Lin cells in mice that
received Ctnnb1fl/fl Esr1-Cre+ BM and that were treated with
TAM (Figures 2C and 2D). Recipients of Apcmin BM showed
similar levels of leukemic cells and a minor reduction in the
lineage-negative (Lin) population. These results indicate that
the combination of IM with genetic deletion of b-catenin reduces
the amount of leukemic disease burden and delays disease
relapse caused by persistent immature leukemia cells in vivo.
Therefore, combined tyrosine kinase inhibition and b-cateninCell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc. 413
Figure 1. Genetic Deletion of b-Catenin after Engraftment of BCR-ABL-Positive Disease Leads to Reduction of Leukemia Cells in Blood and
BM but Does Not Prolong Survival of Recipient Mice
(A) After injection of 70,000 sorted GFP+ cells plus 1 3 106 supporter cells, no significant difference in survival was evident in primary recipient mice of homo-
zygous floxed (HO) or wild-type (WT) BM cells. b-catenin (Ctnnb1) was excised after administration of tamoxifen (TAM) and corn oil served as an ‘‘empty control.’’
(B) Blood counts of moribund animals display significant differences between recipients of homozygous (Ctnnb1fl/fl Cre+) (p = .0149*) and wild-type (Ctnnb1+/+
Cre+) controls.
(C) Organ infiltration (predominantly lung infiltration) was the cause of death in the majority of recipient mice without differential infiltration patterns between the
groups investigated (displayed are representative HE stains of each genetic group). Loss of b-catenin did not influence proliferation (Ki67) of the majority of
transformed cells in spleen and BM. Error bars indicate standard deviation (SD) of three cohorts investigated. Excision control PCR on sorted GFP+ bone marrow
cells from moribund primary recipient mice is indicated in Figure S1.
(D) BM analysis reveals reduction in GFP+ (3-fold reduction in Ctnnb1/ recipients) and GFP+Sca1+ (3-fold reduction in Ctnnb1/ recipient mice) cells. The
left panel demonstrates GFP % and the right panel absolute number of GFP+ cells.
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progression.
Combination of Imatinib Treatment and b-Catenin
Deletion Targets CML Leukemia Stem Cells
To determine whether combination of IM with genetic deletion of
b-catenin could eliminate the LSC population and improve
survival, we evaluated the ability of CML LSCs to maintain
disease in a serial BM transplantation assay, considered the
most stringent test of self-renewal in vivo. Disease was induced
by transduction of BM from mice with the following genotypes:414 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.Ctnnb1fl/fl Esr1-Cre+, Ctnnb1+/fl Esr1-Cre+, and Ctnnb1+/+
Esr1-Cre+. Then we injected 70,000 GFP+ sorted cells together
with 1 3 106 supporter cells in primary mice. Primary recipients
were sacrificed after onset of disease and 150,000 LSC-enriched
GFP+Sca1+ cells were injected into lethally irradiated secondary
recipients with 1 3 106 supporter cells as indicated above.
IM treatment was initiated 7 days after transplantation into
secondary recipient mice and continued for 21 days, combined
with tamoxifen (TAM) administration on days 14–18. Secondary
recipients were sacrificed 2 days after discontinuation of IM
treatment (day 30) for immunophenotypic analysis of BM and
100
1000
10000
100000
0
200
400
600
800
p = .0480* p = .0662
Ctnnb1 +/+ Ctnnb1 -/- Apc
min
W
B
C
/
u
L
S
p
le
e
n
w
e
ig
h
t
in
m
g
10
0
10
1
10
2
10
3
10
4
10
5
10
6
10
1
10
2
10
3
10
4
10
5
Ctnnb1 +/+ Apc
min
Ctnnb1 -/-
p = .0040 ** p = .0042 **
p = .0286 *
G
F
P
+
c
e
ll
s
p
e
r
1
x
1
0
e
6
B
M
c
e
ll
s
G
F
P
+
lin
e
a
g
e
-
c
e
lls
p
e
r
1
x
1
0
e
6
B
M
c
e
lls
1 2 3 4
Imatinib 100mg/KG BID
gavage
Tamoxifen 9mg/40gr
QD i.p.
primary
recipients
injected w 40,000 GFP+ cells
Ctnnb1 fl/fl Esr1-Cre+ (Ctnnb1
-/-
)
Ctnnb1 +/+ Esr1-Cre+ (Ctnnb1
+/+
)
Ctnnb1 +/+ Esr1-Cre- (Ctnnb1
+/+
)
Apc
min
Esr1-Cre- (Apc
min
)
5-FU
marrow
p210 infected
5 6 7week post BMT
GFP & CBC
PB
8
BM & PB
analysis
A
B C
D
GFP
L
in
e
a
g
e
Ctnnb1 +/+ Ctnnb1 -/- Apc
min
Figure 2. Conditional Deletion of b-Catenin Followed by Withdrawal of IM Treatment Leads to Delayed Disease Recurrence
(A) Treatment schedule of primary recipient mice after transplantation with 40,000 GFP+ cells.
(B–D) Endpoint analysis of white blood count (WBC) and BM and spleen weight have been performed at disease onset in the first relapsed animal after
discontinuation of treatment. At this point all remaining animals were sacrificed and analyzed. Disease burden (BCR-ABL-transformed GFP+ cells) was analyzed
as a correlate for relapse (‘‘cytogenetic or hematologic relapse after treatment discontinuation’’).
(B) WBCs are significantly reduced in recipients of Ctnnb1/ BM, compared toCtnnb1+/+ controls. Apcmin mice do not display any differences inWBC or spleen
weight compared to Ctnnb1+/+ animals.
(C and D) BManalysis reveals significant reduction of GFP+ andGFP+LSK cells in theCtnnb1/ recipient cohort. Apcmin mice show similar amounts of GFP+ cells
as WT controls with a minor reduction in the GFP+Lin compartment. Error bars indicate standard deviation of WBCs; n > 4 per cohort displayed.
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Genetic and Pharmacologic Targeting of CML LSCstransplantation of unfractionated BM cells into tertiary recipients
(Figure 3A). We analyzed BM for GFP+ or GFPLinSca1+Kit+
(LSK) cells (Figure 3B, representative plot). The percentage
and total numbers of GFP+Lin and GFP+LSK (enriched for
LSC activity) cells in the TAM-treated animals showed a signifi-
cant decrease compared to control treated animals (Figure 3C).
When 1.53 106 whole BM cells isolated from treated secondaryrecipients were injected into lethally irradiated tertiary recipients,
this resulted in significantly prolonged survival of recipients of
Ctnnb1/ BM (Figure 3D) compared to Ctnnb1+/+ controls
(p = .0019**). Secondary recipients of heterozygous Ctnnb1+/
BM showed a slight but not significant reduction of GFP+LSK
cells. When this BM was transplanted into tertiary recipients,
these animals had a slight but not significant survival benefit asCell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc. 415
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Figure 3. Combination of Genetic Deletion of b-Catenin with IM Treatment Leads to Significant Reduction of CML LSCs in a Serial BMTrans-
plantation Assay
(A) Treatment schedule of secondary recipient mice after transplantation with 150,000 GFP+Sca1+ cells plus supporter cells.
(B) Representative analysis plot of GFP+Lin and GFP+LSK compartments of secondary recipient mice.
(C) Genetic deletion of b-catenin (Ctnnb1) leads to a significant decrease of GFP+Lin (p = .0129*) and GFP+ LSK (p = .005**) cells in secondary recipient mice
when combined with imatinib (IM) treatment. Deletion of b-catenin in combination with IM led to a reduction of GFP+Lin cells from 72,988 in Ctnnb1+/+ recipient
animals to 9,231 inCtnnb1/ recipient animals (calculated as percentage of total harvested BM cells). These numbers correlated with the reduction of GFP+LSK
cells from 2,560 to 194, respectively. Error bars indicate the standard deviation of n = 6 mice investigated in the cohort displayed.
(D) Transplantation of 1.5 3 106 whole BM cells leads to a significant survival advantage in tertiary recipients of Ctnnb1/ BM when compared to Ctnnb1+/+
controls. Transplantation of higher cell numbers (6 3 106 whole BM cells) is displayed in Figure S2.
(E and F) Analysis of disease burden at different time points by flow cytometry (E) or nested RT-PCR (F) showed a significant decrease in disease load in
Ctnnb1/ tertiary recipient mice. These results could be recapitulated with Mx1-Cre (Figures S2C–S2E).
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compare disease burden in tertiary recipient mice, we investi-
gated the peripheral blood for GFP+ cells after the development416 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.of lethal disease in the first animal (Figures 3D and 3E). A
significant difference in total number and percentage of GFP+
cells was evident at that time between recipient animals of
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Genetic and Pharmacologic Targeting of CML LSCsCtnnb1+/+ and Ctnnb1/ BM (Figure 3E). Because several mice
developed disease in the Ctnnb1+/+ cohort but none of the
Ctnnb1/ became sick, we aimed to analyze the molecular
disease burden as determined by BCR-ABL transcript detection
in the peripheral blood by nested-RT-PCR. PCR primers for the
human p210 BCR-ABL construct were used together with
murine Gapdh controls. None of the ten living animals that
received Ctnnb1/ BM had any b3a2-transcript detectable,
while two out of five remaining animals that received Ctnnb1+/+
BM showed positivity for a BCR-ABL transcript (Figure 3F).
The other five animals in the Ctnnb1+/+ cohort had already suc-
cumbed to MPN, and BM and spleen infiltration by GFP+
(BCR-ABL+) cells had been confirmed.
We repeated the experiment with a higher cell number of un-
fractionated BM cells for injection into tertiary recipients. With
6 3 106 whole BM cells, one out of five mice developed GFP+
MPN in the Ctnnb1/ recipient group whereas all of the
Ctnnb1+/+ recipients succumbed to disease (Figure S2A). More-
over, all of the recipients of heterozygous floxed BM (Ctnnb1+/)
developed lethal MPN but with a slightly longer latency than the
wild-type recipient control. Analysis of disease burden on day 36
after transplantation revealed significantly lower GFP+ cells in
the peripheral blood of Ctnnb1/ mice compared to wild-type
and heterozygous controls (Figure S2B).
Although only one of five animals in the Ctnnb1/ (6 3
106 cells injected) cohort had succumbed to disease, we used
transplants performed at limiting cell number to determine the
estimated LSC frequency. With the two data points available
(dilutions of 6 3 106 and 5 3 105), we estimate an approximate
35-fold decrease in LSCs. Taken together, our data show
a dramatic reduction in LSC frequency.
Because there have been recent reports that highlight Esr1-
Cre-related toxicity on myelopoiesis (Higashi et al., 2009), we
aimed to clarify the impact of b-catenin deletion on the reduction
or disappearance of LSCs in our model, so we repeated the
genetic model applied with the well-characterized Mx1-Cre
model (Figures S2C–S2E). IM treatment was started on day 14
(100 mg/KG per gavage BID). Mice were injected on days 15,
17, and 19with poly(I:C) at a dose of 12.5 mg/g bodyweight. After
a treatment period of 21 days of IM, mice were sacrificed. We
analyzed the BM (as indicated below) to determine the amount
of immunophenotypic LSCs (GFP+LSK cells). This analysis
showed an approximately 10-fold reduction in GFP+LSK cells.
In order to determine the number of functional LSCs, we trans-
planted dilutions of total BM (5 3 105 and 6 3 106 cells) into
secondary recipient mice. Animals in the 6 3 106 Ctnnb1+/+
cohort developed lethal MPN within 45 days after transplanta-
tion, whereas only 25% of the Ctnnb1/ mice died of MPN.
When the graft was diluted to 5 3 105 cells, only 20% of the
Ctnnb1+/+ but none of the mice with a Ctnnb1/ genotype
developed disease. This functional data set with the established
Mx1-Cre system suggests a 10-fold reduction of LSCs
(Figure S2E).
Indomethacin Is Effective in Modulating b-Catenin
Levels and Synergizes with IM in CML
To address whether modulation of Wnt/b-catenin signaling can
be achieved pharmacologically in CML stem cells, we aimed
to inhibit or enhance b-catenin levels in the human BCR-ABL-positive cell line K562. Although inhibition of b-catenin may
contribute to reduction of LSCs, stimulation of b-catenin activity
could potentially bring LSCs into cycle and therefore make them
more susceptible to IM treatment (Scheller et al., 2006). More-
over, there is evidence that inhibition of GSK3, which should
activate b-catenin, is an effective approach for AML (Holmes
et al., 2008; Wang et al., 2008). As it is known that inhibition of
prostaglandin signaling via COX2 inhibitors can decrease
b-catenin level in HSCs and LSCs, we utilized indomethacin to
inhibit and the GSK3 inhibitor BIO ((20Z,30E)-6-Bromoindirubin-
30-oxime) to stimulate Wnt/b-catenin pathway activity.
Treatment of BCR-ABL-rearranged K562 cells with either
indomethacin or IM led to reduction of b-catenin protein levels,
but the combination of both drugs led to almost complete abro-
gation of b-catenin in vitro (Figure 4A). In contrast, incubation
with the GSK3b inhibitor BIO caused pronounced accumulation
of b-catenin. These stimulative BIO effects could be partially
reversed by coincubation with indomethacin and IM. Next we
developed a flow cytometry-based assessment of b-catenin so
that we could assess levels in small numbers of cells. When
we assessed b-catenin levels in K562 cells treated with BIO
and indomethacin, we found similar results to our immunoblot
experiments (Figure 4B, left).
Because BIO and indomethacin proved to effectively modu-
late b-catenin in the cell culture model, and indomethacin even
synergized with IM in b-catenin suppression, we aimed to
confirm these modulatory effects and capacity in the LSC-
enriched population from mice with BCR-ABL-induced MPN.
Mouse BM cells were transduced with the BCR-ABL retrovirus
after 5-FU treatment and injected into primary (lethally irradiated)
recipient mice as described above. Primary recipient mice were
sacrificed on day 20 after transplantation and BMwas harvested
and sorted for GFP+Sca1+ cells. This LSC-containing population
was treated with either DMSO, IM, indomethacin, or BIO. Flow
cytometry revealed increased b-catenin levels in BIO-treated
GFP+Sca1+ cells, and a reduction of b-catenin could be detected
in IM- or indomethacin-treated cells (Figure 4B, right). Addition-
ally, we treated GFP+Sca1+ cells ex vivo with BIO, PGE2, indo-
methacin, or DMSO and then plated them in methylcellulose.
This revealed decreased colony formation upon indomethacin
treatment whereas enhancement of b-catenin with BIO or
PGE2 did not show any significant change in colony formation
(Figure 4C). When we tested primary recipient mice for induction
of cell cycle by GSK3 inhibition, we found that administration of
BIO led to induction of cell cycle in GFP-negative LSK, but the
induction was evenmore pronounced in GFP-positive LSKs (Fig-
ure S3A). Because we aimed to link indomethacin treatment with
effects on b-catenin levels in CML LICs, we performed an ELISA-
based assay for detection of cAMP levels on GFP+Sca1+ cells.
Low levels of cAMP were detected in the DMSO-treated
controls; however, treatment with indomethacin lowered the
cAMP levels in the GFP+Sca1+ leukemia-initiating fraction (as
indicated by increase in absorbance; Figure S3B). Although
this is not a functional assay, decrease of cAMP levels by indo-
methacin treatment in the leukemia-initiating population links
the functional data to the mechanism of PGE2 stimulation of
HSCs, which was through stimulation of cAMP levels and PKA
phosphorylation of b-catenin (Goessling et al., 2009). These
data show that indomethacin works together with IM to suppressCell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc. 417
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Figure 4. Modulation of Prostaglandin Signaling
Leads to Alteration of b-Catenin Levels and Influ-
ences Colony Formation
(A) Western blotting on whole-cell lysates of K562 cells.
Incubation of K562 cells with either IM (1 mM) or indo-
methacin (40 mM) led to reduction of b-catenin protein
levels, while combined treatment revealed profound
decrease of b-catenin. Increase of b-catenin levels were
detectable upon GSK3b inhibition with BIO (0.5 mM) and
partially reversible by cotreatment with IM and indo-
methacin.
(B) Using low cell numbers, these results could be vali-
dated with intracellular flow cytometry in K562 cells (left)
and in GFP+Sca1+ leukemic cells from primary mice
(right).
(C) When plated in methylcellulose, indomethacin-treated
GFP+Sca1+ cells sorted from primary recipient mice
(n = 3 mice/group, error bars indicate SD) showed
significantly impaired colony formation compared to
DMSO-, BIO-, or PGE2-treated cells (p = .0109). Evalua-
tion of b-catenin modulation in CML LICs derived from
recipient mice after drug treatment is shown in Figure S3.
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the combination.
Imatinib plus Indomethacin Prolongs Survival in a Serial
Murine BM Transplantation Model
Because inhibition of PGE2 signaling suppressed b-catenin
levels in CML cells, we aimed to elucidate whether cotreatment
with indomethacin and IM could effectively reduce the number of
LSCs and could lead to delayed onset of disease in a serial trans-
plantation approach. As described above, 150,000 GFP+Sca1+
cells isolated from mice with a primary BCR-ABL-induced CML
were injected into secondary recipients along with supporter
BM cells. These mice were treated with IM (d7–d28) and indo-
methacin or vehicle control (d14–d18, d21–d25) (Figure 5A). After
28 days, all mice were sacrificed and analyzed in detail (Fig-
ure 5B). Normal spleen size and white blood counts of treated
secondary recipients indicated efficacy of IM only and of IM
plus indomethacin treatment (Figures S4A and S4B). Strikingly,
we observed a significant reduction of GFP+LSK cells in the
indomethacin-plus-IM-cotreated animals compared to IM-only
controls (Figure 5C). However, the numbers of normal LSK cells
(GFP, derived from supporter BM) were not affected by any
cotreatment (data not shown).
To investigate the functional relevance of this reduction, we
injected 2 3 106 whole BM cells into tertiary recipient mice and
monitored these animals for onset of disease. All tertiary recipi-
ents of the IM-only-treated BM developed lethal disease within
36 days after BM transplantation. However, recipients of
IM-plus-indomethacin-cotreated BM showed delayed onset of
disease and a significantly prolonged survival of up to 62 days
after transplantation (Figure 6A, p < .0001***). In contrast to
previous reports that the deletion of b-catenin via vav-Cre before
transformation with BCR-ABL had resulted in development of
acute lymphoblastic leukemia rather than CML (Zhao et al.,418 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.2007), we observed that both treatment groups developed
morphologically and immunophenotypically similar MPN (Fig-
ures 6B and 6C), despite delayed onset of disease in the indo-
methacin-plus-IM-treated group. Because activation of canon-
ical Wnt signaling in our genetic model (using Apcmin mice) had
not shown any significant reduction in disease burden, we also
aimed to elucidate whether pharmacological stimulation of
b-catenin could have an effect on LSC frequency or survival of
tertiary recipient mice. Stimulation of b-catenin by cotreatment
with the GSK3b inhibitor BIO resulted in a minor decrease of
GFP+Lin andGFP+LSK cells in secondary animals (Figure S4C).
However, this did not translate into any survival benefit of tertiary
recipients (Figure S5).
In order to correlate these findings of our mouse model with
human data, we analyzed a previously published data set that
investigated CD34+ cells from IM-naive chronic-phase CML
patients to predict responses upon IM treatment (McWeeney
et al., 2010). Interestingly, supervised analysis comparing
responders versus nonresponders revealed the prostaglandin-
endoperoxide synthase (PTGS2, also called cyclooxygenase-2)
among the top candidates. PTGS2 expression levels were signif-
icantly lower in the ‘‘responder’’ cohort (p = 0.0067, Figure 6D),
thereby confirming that inhibition of PTGS2/COX2 may translate
into molecular responses (and therefore targeting LSCs). More-
over, we found a molecular signatures database (MSigDB)
gene set defined by genes down- or upregulated in CD4+ T
lymphocytes after stimulation with prostaglandin E2 (MSigDB
gene set CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2,
M2214) to be significantly enriched in the responder versus non-
responder associated gene expression pattern (p = 0.0284).
Finally, clustering of the CML samples based only on genes in-
volved in prostanoid hormones (MSigDB gene set REACTOME_
PROSTANOID_HORMONES,M14714) correlatedwith response/
nonresponse, and thus showed decreased expression levels
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Figure 5. Pharmacologic Inhibition of PGE2 Signaling in Combination with IM Treatment Leads to Reduction of LSCs in a Serial BM Trans-
plantation Assay In Vivo
(A) Treatment schedule of secondary recipient mice (nR 8 mice/cohort) injected with 150,000 GFP+Sca1+ cells out of primary recipient mice.
(B) Representative analysis plot of GFP+Lin and GFP+LSK compartments of secondary recipient mice after treatment.
(C) Cotreatment of secondary recipient mice with IM and indomethacin leads to reduction of GFP+Lin cells (p = .0635) and to significant depletion of GFP+LSK
cells (p = .0159) in the BM. GFP+Lin cells were reduced from 42,560 (IM-only group) to 9,867 (IM+INDO-treated cohort). This translated into a significant
reduction of GFP+LSK cells from 823 to 146, respectively. (Error bars indicate SD of GFP-positive cells; n > 4 per cohort investigated.) Evaluation of secondary
recipients after drug combination therapy is displayed in Figure S4.
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response (p = 0.0067, Figure 6E).These data provide evidence
for an approach to target CML stem cells through the inhibition
of Wnt/b-catenin signaling in combination with tyrosine kinase
inhibitors by using a widely available and affordable clinical
therapeutic (indomethacin).
DISCUSSION
TheWnt/b-catenin pathway has been shown to be necessary for
HSC development but not for HSC maintenance in fully devel-
oped stem cells (Koch et al., 2008; Zhao et al., 2007). Also, b-cat-
enin has been shown to be necessary for development of LSCs
in a mouse model of BCR-ABL-induced MPN (Hu et al., 2009;
Zhao et al., 2007). However, these data do not address the crit-
ical question as to whether b-catenin is required for maintenance
of LSCs after the establishment of BCR-ABL-induced disease.
This is a critical question that will help guide development of
therapeutics that target the Wnt/b-catenin pathway in patients
with CML who are maintained on tyrosine kinase inhibitors. We
hypothesized that inhibition of canonical Wnt signaling could
potentially affect the maintenance of IM-resistant CML stemcells, thereby providing synergy when used in conjunction with
IM treatment. To address this question, we conditionally inacti-
vated b-catenin after engraftment of BCR-ABL-transformed
HSCs/LSCs. Although we and others have had extensive expe-
rience with the hematopoietic-specific Mx1-Cre recombinase,
the induction of cre expression in this model is induced by an
interferon response through the injection of poly(I:C) in mice.
Interferon was the standard therapy (alone or in combination
with cytarabine) for CML for almost a decade and is known to
induce complete cytogenetic remissions (Guilhot et al., 1997).
Therefore, using Mx1-Cre in a conditional b-catenin knockout
model could potentially confound our results through the antileu-
kemic effects of elevated interferon levels. We therefore chose
in the first set of experiments a tamoxifen (TAM)-inducible
estrogen-receptor Cre recombinase. However, because there
have been recent reports that highlight Esr1-Cre-related toxicity
on myelopoiesis (Higashi et al., 2009), we repeated our experi-
ments using the Mx1-Cre system with consistent results. A
caveat when using the retroviral transduction model for BCR-
ABL is the requirement of cell division for retroviral integration.
Therefore, only dividing HSCs will be transformed by the onco-
gene. However, by 2 weeks after transplantation of theseCell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc. 419
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Figure 6. Prostaglandin Signaling Is Relevant as a Target in CML LSCs and Has Prognostic Relevance in Human CML
(A–C) Pharmacologic inhibition of PGE2 signaling in combination with IM treatment leads to delayed onset of disease in tertiary recipient mice. Injection of
1.5 3 106 whole BM cells leads to delayed onset of disease in tertiary recipients of IM-plus-indomethacin-treated BM cells in comparison to IM-only-treated
controls (A). Endpoint analysis of moribund animals revealed no difference in disease phenotype in the different treatment arms with regard to white blood
count, spleen weight (B), or peripheral blood/organ involvement (C). Error bars indicated standard deviation of all mice (n > 13) investigated in both cohorts
investigated.
(D and E) Gene expression profiling of CML patient-derived CD34+ cell samples (D, E) reveals a prognostically relevant PGE2 signature. Expression levels of
prostaglandin synthetase 2 correlate with molecular response in the data set investigated (p = 0.0004) (McWeeney et al., 2010). Moreover, sample clustering
based on the ‘‘REACTOME_PROSTANOID_HORMONES’’MSigDB gene set correlates alsowith response/nonresponse in this data set (p = 0.0067) (E). Figure S5
shows survival of tertiary recipient mice after combination of imatinib and BIO in secondary donor animals.
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LSK cells remains in G0 in cell cycle analysis before Esr1-Cre-
or Mx1-Cre-mediated excision of b-catenin was initiated. Upon
IM monotherapy, an increasing fraction of stem cells remains
quiescent in the BM. This indicates—at least in part—that420 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.also a temporarily quiescent fraction of stem cells can be
affected by genetic deletion of b-catenin.
Unexpectedly, conditional deletion of b-catenin did not result
in significant prolongation of survival in primary recipient mice
and all recipients died as a result of organ infiltration. However,
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Genetic and Pharmacologic Targeting of CML LSCsin the peripheral blood and BM, a clear reduction of GFP+ cells
was detectable. Thus, these data support the tenet that deletion
of b-catenin may result in reduction of LSCs, but may spare
the differentiated progenitors, most probably because of a lack
of dependence on b-catenin signaling for survival of this
population. Furthermore, these results may reflect differences
in the experimental design compared to previously reported
results—when b-catenin was deleted in early development
(Zhao et al., 2007) or simultaneously to transformation with
BCR-ABL with a fusion retrovirus vector (Hu et al., 2009). In
our model, differentiated progenitor cells had already infiltrated
different organ sites prior to b-catenin deletion. These data
demonstrate that therapeutic approaches which largely target
LSCs will need to be combined with therapeutics that predomi-
nately target progenitors (like Imatinib) in order to abrogate the
detrimental effects of the high progenitor burden.
In order to target LSC populations and to simulate a clinically
relevant setting for patients with CML that targets residual
disease in tyrosine kinase inhibitor-treated patients, we com-
bined IM treatment with genetic modulation of b-catenin. Based
on previous studies, there was rationale to test b-catenin loss of
function in combination with IM. However, there is growing
evidence that activation of Wnt signaling results in alteration of
HSCs. Wnt/b-catenin activation by stabilization of b-catenin
has been shown to lead toHSC exhaustion due to cell cycle entry
and consecutive apoptosis after initial expansion of the HSC
pool (Scheller et al., 2006). Less pronounced activation with
a GSK3b inhibitor led to increase of the HSC pool and enhanced
repopulation capacity (Trowbridge et al., 2006). These data sug-
gested that activation of Wnt signaling might lead to increased
proliferation of the LSC pool and therefore increase susceptibility
to IM treatment. However, it was unclear whether activation or
inhibition of this pathway would be most beneficial in the context
of IM therapy. Thus, we decided to assess either loss-of-function
or constitutive activation models of the Wnt/b-catenin pathway.
We induced CML by transformation of murine stem and progen-
itor cells with the human p210-BCR-ABL oncogene. IM treat-
ment was initiated after engraftment of transformed cells and
confirmed with either genetic deletion (by administration of
tamoxifen in Ctnnb1fl/fl Esr1-Cre+ BMC) or activation (Apcmin
BM) of Ctnnb1. Whereas activation of b-catenin seemed to leave
the disease-initiating population largely unaffected, deletion of
b-catenin led to reduction of LSCs as displayed by delayed
and reduced recurrence of disease. The specific effect of b-cat-
enin deletion on LSC self-renewal was manifest by an inability of
Ctnnb1/ marrow to maintain disease through subsequent
generation of recipients in a serial BM transplantation assay.
Genetic deletion in combination with IM treatment led to abroga-
tion of LSCs in secondary (treated) recipients and delayed
disease kinetics in tertiary recipient mice. Not only did we
observe delayed onset of disease, there was also a 10- to 35-
fold reduction in LSC frequency from secondary mice trans-
planted with b-catenin-depleted leukemia compared to WT
controls, demonstrating a striking and potent effect on LSCs
that might be utilized for clinical gain.
As targeted therapies are currently developed for a variety of
solid tumors (Alvarez et al., 2010; De Roock et al., 2011) and
leukemia (Fischer et al., 2010; Mason et al., 2009), we aimed to
investigate whether canonical Wnt signaling could becomea ‘‘druggable’’ target in patients with minimal residual disease
CML. Activation of canonical Wnt signaling is known to be
an important oncogeneic event in solid tumors, especially in
colon carcinomas (Behrens, 2000; Oving and Clevers, 2002)
and long-term treatment with COX-inhibitors/nonsteroidal-anti-
inflammatory drugs (NSAID) has been found to reduce the rela-
tive risk for colon carcinoma development (Gupta and Dubois,
2001; Rothwell et al., 2010). Recently, reduction of tumor inci-
dence has been reported for long-term use of the COX-inhibitor
acetylsalicylic acid (aspirin) for a variety of cancers, providing
provocative evidence that dysregulated Wnt signaling may be
a common feature of many malignancies (Rothwell et al.,
2011). In the hematopoietic system, perturbations in the COX-
Prostaglandin-Wnt cascade have been shown to have important
effects on HSC and LSC function (Goessling et al., 2009; Wang
et al., 2010). Stimulation of Wnt signaling with PGE2 has been
shown to enhance HSC homing, survival, and proliferation
(Frisch et al., 2009; Hoggatt et al., 2009; Goessling et al.,
2009). Conversely, reduction of b-catenin levels with the COX
inhibitor indomethacin significantly decreases MLL-AF9 LSC
frequency (Wang et al., 2010). To elucidate the role of pharmaco-
logical b-catenin modulation in this CML model, we investigated
both stimulation (via the GSK3b inhibitor BIO) and inhibition
(via the COX inhibitor indomethacin) of b-catenin in combination
with IM treatment in vivo. As indicated by small spleen sizes
and normal white blood counts, imatinib was an effective therapy
against transformed progenitors and differentiated cells in
secondary recipients. Given the difficulty with limiting dilution
transplantation experiments in this model, we used survival of
tertiary recipient mice as an indicator of LSC function. This
experimental design has been used as an alternative for assess-
ment of LSC function in CML and AML LSC models (Hu et al.,
2009; Zhao et al., 2007). With this serial transplantation assay,
we did not observe biologically significant results on LSC func-
tion by the combination of BIO (leading to Wnt activation) and
IM. However, our results indicate that reduction of the b-catenin
level via indomethacin leads to delayed onset of disease (in
tertiary recipients) as a result of LSC reduction in the secondary
recipient mice. This finding is consistent with analyses of gene-
expression data sets that were previously published on CD34+
cells of CML patients and have been correlated with response
to IM treatment. Patients that show enrichment for prostaglandin
signaling-related signatures show inferior molecular responses
upon IM therapy.
In summary, we have demonstrated that targeting b-catenin
by genetic deletion or drug treatment is an effective combination
therapy with IM and eradicates LSCs that remain after IM treat-
ment. This leads to a delayed recurrence of CML after IM discon-
tinuation, providing support for the notion that targeting LSCs
will be an effective combination approach with tyrosine kinase
inhibitors in this and perhaps other diseases. Recent reports
indicate that adult HSCs do not require fully active b-catenin
for maintenance (Koch et al., 2006; Luis et al., 2011), and our
data show that that pharmacologic inhibition of b-catenin leads
to reduction of GFP+ (BCR-ABL-transformed) LSK cells, thus
suggesting a therapeutic index. However, this difference has
not been addressed yet in a human setting. Therefore, establish-
ing a therapeutic index between normal HSCs and LSCs in
human CML after b-catenin modulation and IM treatment willCell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc. 421
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trials. These findings prompt an important question as to why
CML LSCs are dependent upon b-catenin whereas normal
HSCs are less dependent on this pathway. The answer to this
question will be the focus of much future work, and is likely to
point to further vulnerabilities in cancer stem cells that can be
targeted for therapeutic purposes. Finally, these data provide
a rational template and preclinical model for the development
and utilization of b-catenin-targeted therapies to eradicate
LSCs in patients with CML.
EXPERIMENTAL PROCEDURES
Bone Marrow Infection and Transplantation
Murine BM transplantation was performed as previously described (Hu et al.,
2009). Donor mice (C57BL/6, Charles River Labs, Wilmington, MA) were
injected with 150 mg/KG 5-FU i.v. and BM was harvested on day 5. BM cells
were infected by colocalization of virus supernatant (containing IL-3, IL-6, and
SCF) (Peprotech, Rocky Hill, NJ) with mouse BM cells on retronectin-coated
plates. Infection was repeated after 24 hr. One day after second infection,
GFP+ cells were sorted with a FACSAria and used for transplantation. For
transplantation, GFP+ BM cells were transplanted via lateral tail vein injection
into lethally irradiated (1,100 cGy, split-dose) 4- to 6-week-old C57BL/6 mice
(Jackson Laboratories, Bar Harbor, ME) in the presence of 1 million freshly iso-
lated erythrocyte-lysed ‘‘supporter’’ BM cells. For serial transplantation exper-
iments, BM of primary recipient mice was harvested and 150,000 GFP+Sca1+
sorted cells were injected into secondary recipients. Tertiary recipient mice
were injected with whole BM cells, harvested from secondary recipients after
treatment was discontinued.
Drug Treatment of Mice
Imatinib was dissolved in PBS solution at a stock solution of 100 mg/ml and
administered by oral gavage twice daily at a single dose of 100 mg/kg. Indo-
methacin and BIO (6-Bromoindirubin-30-oxime) (both Sigma, St. Louis, MO,
USA) were diluted in DMSO and administered by i.p. injection at a dose of
4mg/kg/day and 50 mg/kg/day, respectively. DMSOwas injected as a negative
control.
Methylcellulose Colony Formation Assay
For investigation of colony formation in methylcellulose, BM cells of primary
CML mice were harvested on day 21 after BMT and sorted for GFP+Sca1+
cells. Cells were treated ex vivo with either BIO (0.5 mM), PGE2 (10 mM, Sigma),
or indomethacin (40 mM) for 48 hr and 1,000 cells were plated subsequently in
1.1 ml of methylcellulose (M3234, Stem Cell Technologies), supplemented
with cytokines (IL-3, IL-6, SCF). Colony numbers were counted on day 8 after
plating.
Flow Cytometry
For immunophenotype analysis, peripheral blood cells, BM, or spleen cells
were resuspended in PBS/1% FBS after erythrocyte lysis (PharmLyse, BD
PharMingen, San Diego, CA). Sorting and analysis of LSK cells or Sca1+ cells
was performed as previously described (Krivtsov et al., 2009). Intracellular flow
cytometry was performed as described previously (Kalaitzidis and Neel, 2008)
with a primary antibody against Ctnnb1 (Clone 8e4, A.G. Scientific, San Diego,
CA) followed by a secondary Alexa 594-labeled antibody (A31623, Invitrogen,
Carlsbad) and analyzed with a LSRII (Becton Dickinson) cytometer. Analysis
was performed with FlowJo software (Treestar, Ashland, OR).
Western Blotting
Western blot experiments were performed as described previously (Heidel
et al., 2006) with antibodies for total b-catenin (BD Transduction Lab, No.
61054).
PCR Assays
For qualitative detection of BCR-ABL, a nested-PCR assay was performed
with 200 ml of whole blood. RNAwas prepared with TRIzol Reagent (Invitrogen,422 Cell Stem Cell 10, 412–424, April 6, 2012 ª2012 Elsevier Inc.Carlsbad, CA). cDNA was transcribed from 1 mg of RNA with the Tetro cDNA
Synthesis Kit (Bioline, Taunton, MA). 40 cycles of PCR were conducted.
Primers are indicated in the Supplemental Information. This resulted in ampli-
fication of a 475 bp fragment (b3a2 breakpoint) of the human p210 BCR-ABL
construct.
Statistics and Analysis of Gene Expression Data
For survival analysis, Kaplan-Meier curves were plotted with GraphPad Prism
version 5.00 (GraphPad Software, San Diego, CA). Differences between
survival distributions were analyzed with the logrank test. Statistical analyses
were performed with Student’s t test (normal distribution) or Mann-Whitney U
test (when normal distribution was not given). p less than .05 was considered
statistically significant (*p < .05, **p < .01, and ***p < 0.001).
Published gene expression data (GSE14671) (McWeeney et al., 2010) and
curated gene sets (M2214 and M14714) were downloaded from Gene Expres-
sion Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and the Molecular
Signatures Database (MSigDB v3.0, http://www.broadinstitute.org/gsea/
msigdb/index.jsp), respectively. Gene expression data were normalized and
analyzed as previously reported (Lu¨ck et al., 2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/j.
stem.2012.02.017.
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